Cargando…

A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR

Since 2020, the COVID-19 pandemic has spread worldwide, causing health, economic, and social distress. Containment strategies rely on rapid and consistent methodology for molecular detection and characterization. Emerging variants of concern (VOCs) are currently associated with increased infectivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabiani, Marco, Margiotti, Katia, Sabatino, Manuela, Viola, Antonella, Mesoraca, Alvaro, Giorlandino, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954379/
https://www.ncbi.nlm.nih.gov/pubmed/35335115
http://dx.doi.org/10.3390/vaccines10030483
_version_ 1784676079404843008
author Fabiani, Marco
Margiotti, Katia
Sabatino, Manuela
Viola, Antonella
Mesoraca, Alvaro
Giorlandino, Claudio
author_facet Fabiani, Marco
Margiotti, Katia
Sabatino, Manuela
Viola, Antonella
Mesoraca, Alvaro
Giorlandino, Claudio
author_sort Fabiani, Marco
collection PubMed
description Since 2020, the COVID-19 pandemic has spread worldwide, causing health, economic, and social distress. Containment strategies rely on rapid and consistent methodology for molecular detection and characterization. Emerging variants of concern (VOCs) are currently associated with increased infectivity and immune escape (natural defence mechanisms and vaccine). Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively. Here, a rapid and low-cost technique was validated to distinguish the Alpha, Beta, Gamma, and Delta SARS-CoV-2 variants by detecting spike gene mutations using a real-time reverse transcription polymerase chain reaction methodology (RT-PCR). A total of 132 positive patients affected by coronavirus disease-19 (COVID-19) were analysed by employing RT-PCR to target single-nucleotide polymorphisms (SNPs) to screen spike protein mutations. All data were validated by the next-generation sequencing (NGS) methodology and using sequences from a public database. Among 132 COVID-19-positive samples, we were able to discriminate all of the investigated SARS-CoV-2 variants with 100% concordance when compared with the NGS method. RT-PCR -based assays for identifying circulating VOCs of SARS-CoV-2 resulted in a rapid method used to identify specific SARS-CoV-2 variants, allowing for a better survey of the spread of the virus and its transmissibility in the pandemic phase.
format Online
Article
Text
id pubmed-8954379
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89543792022-03-26 A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR Fabiani, Marco Margiotti, Katia Sabatino, Manuela Viola, Antonella Mesoraca, Alvaro Giorlandino, Claudio Vaccines (Basel) Article Since 2020, the COVID-19 pandemic has spread worldwide, causing health, economic, and social distress. Containment strategies rely on rapid and consistent methodology for molecular detection and characterization. Emerging variants of concern (VOCs) are currently associated with increased infectivity and immune escape (natural defence mechanisms and vaccine). Several VOCs have been detected, including Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1/B.1.1.28.1) and Delta variant (B.1.617.2), first identified in the UK, South Africa, Brazil and India, respectively. Here, a rapid and low-cost technique was validated to distinguish the Alpha, Beta, Gamma, and Delta SARS-CoV-2 variants by detecting spike gene mutations using a real-time reverse transcription polymerase chain reaction methodology (RT-PCR). A total of 132 positive patients affected by coronavirus disease-19 (COVID-19) were analysed by employing RT-PCR to target single-nucleotide polymorphisms (SNPs) to screen spike protein mutations. All data were validated by the next-generation sequencing (NGS) methodology and using sequences from a public database. Among 132 COVID-19-positive samples, we were able to discriminate all of the investigated SARS-CoV-2 variants with 100% concordance when compared with the NGS method. RT-PCR -based assays for identifying circulating VOCs of SARS-CoV-2 resulted in a rapid method used to identify specific SARS-CoV-2 variants, allowing for a better survey of the spread of the virus and its transmissibility in the pandemic phase. MDPI 2022-03-21 /pmc/articles/PMC8954379/ /pubmed/35335115 http://dx.doi.org/10.3390/vaccines10030483 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fabiani, Marco
Margiotti, Katia
Sabatino, Manuela
Viola, Antonella
Mesoraca, Alvaro
Giorlandino, Claudio
A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR
title A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR
title_full A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR
title_fullStr A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR
title_full_unstemmed A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR
title_short A Rapid and Consistent Method to Identify Four SARS-CoV-2 Variants during the First Half of 2021 by RT-PCR
title_sort rapid and consistent method to identify four sars-cov-2 variants during the first half of 2021 by rt-pcr
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954379/
https://www.ncbi.nlm.nih.gov/pubmed/35335115
http://dx.doi.org/10.3390/vaccines10030483
work_keys_str_mv AT fabianimarco arapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT margiottikatia arapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT sabatinomanuela arapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT violaantonella arapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT mesoracaalvaro arapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT giorlandinoclaudio arapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT fabianimarco rapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT margiottikatia rapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT sabatinomanuela rapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT violaantonella rapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT mesoracaalvaro rapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr
AT giorlandinoclaudio rapidandconsistentmethodtoidentifyfoursarscov2variantsduringthefirsthalfof2021byrtpcr